Pacific Biosciences of California PACB Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacific Biosciences of California's other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacific Biosciences of California's other accrued liabilities?
- Pacific Biosciences of California (PACB) reported other accrued liabilities of $1.24M in Q1 2026.
- How has Pacific Biosciences of California's other accrued liabilities changed year-over-year?
- Pacific Biosciences of California's other accrued liabilities decreased by 77.8% year-over-year, from $5.57M to $1.24M.
- What is the long-term trend for Pacific Biosciences of California's other accrued liabilities?
- Over 5 years (2020 to 2025), Pacific Biosciences of California's other accrued liabilities has grown at a -14.8% compound annual growth rate (CAGR), from $4.52M to $2.03M.
- What does other accrued liabilities mean?
- This captures miscellaneous short-term obligations that do not fit into standard categories like accounts payable or accrued compensation. It often includes items such as customer deposits, short-term tax provisions, or other minor contractual liabilities. It provides insight into the breadth of the company's short-term financial commitments.